ProCE Banner Activity

Lenalidomide Maintenance after ASCT Improved OS in Newly Diagnosed MM

Slideset Download
Conference Coverage
A meta-analysis of 3 phase III trials shows lenalidomide maintenance after ASCT significantly increased OS by an estimated 2.5 yrs vs placebo or no maintenance in patients with newly diagnosed multiple myeloma.

Released: June 06, 2016

Expiration: June 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals